Low availability of haematin (hemin) in Pakistan

Madam, Acute Intermittent Porphyria (AIP) is an autosomal dominant disorder that results from a defect in the enzyme named porphobilinogen deaminase.1 It is symptomatic porphyria, involving the accumulation of porphyrins and porphyrin precursors due to impaired conversion in haeme synthesis. Acute...

Full description

Saved in:
Bibliographic Details
Main Authors: Fatima Ahsan, Muhammed Ifham Mohamed Imtiyas, Abdul Raheem Rizvie
Format: Article
Language:English
Published: Pakistan Medical Association 2024-10-01
Series:Journal of the Pakistan Medical Association
Subjects:
Online Access:https://jpma.org.pk/index.php/public_html/article/view/10726
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850098481963728896
author Fatima Ahsan
Muhammed Ifham Mohamed Imtiyas
Abdul Raheem Rizvie
author_facet Fatima Ahsan
Muhammed Ifham Mohamed Imtiyas
Abdul Raheem Rizvie
author_sort Fatima Ahsan
collection DOAJ
description Madam, Acute Intermittent Porphyria (AIP) is an autosomal dominant disorder that results from a defect in the enzyme named porphobilinogen deaminase.1 It is symptomatic porphyria, involving the accumulation of porphyrins and porphyrin precursors due to impaired conversion in haeme synthesis. Acute Intermittent Porphyria is clinically characterized by acute episodes of multiple gastrointestinal and neurologic symptoms; during which the patient remains healthy between episodes.2 Acute Intermittent Porphyria episodes are commonly observed in post pubertal females. The most common symptoms include periodic abdominal pain, vomiting and hypertension followed by neurologic damage that leads to peripheral and autonomic neuropathies (mostly motor) and psychiatric manifestations.2 Hormonal cycle regulation may worsen porphyria, since its symptoms coincide with the menstrual cycle. Although positive response has been noted in hormonal suppression by gonadotropin releasing hormone agonists.3 Currently, the most widely used treatment is hemin, a form of haeme that can be given intravenously. Its administration reduces the haeme deficit, hence limits the production of porphyrins precursors by the body. Availability of hemin in Pakistan is not promising while alternatives such as intravenous infusion of glucose, and pain relievers like Nalbuphine, a man-made opioid analgesic, and Morphine are short-term treatments. Haeme Arginate (HA), a compound of haeme and arginine, is equivalent to hematin in the treatment of AIP. Long-term weekly intravenous infusions of prophylactic HA prevent severity and frequency of porphyric attacks in patients with AIP.4 While haeme therapy is recommended if a patient exhibits neurological impairment, liver transplant appears to be the last resort in patients with recurrent clinical manifestations. To effectively mediate the growing need of Hemin in Pakistan, a systematic plan with effective and immediate steps must be introduced. The regulatory authorities must expedite the approval and licensing process of appropriate medication that would meet the growing need of the country, while not compromising on its quality. The possibility of local production should be explored, while strengthening international ties aimed at importing affordable medication. The government should focus on initiating partnerships with international organizations, non-governmental organizations (NGOs) and global health initiatives. Nationwide workshops and informative campaigns towards healthcare work should be a priority, to raise awareness of the situation and the proper steps that should be taken to minimize its adverse effects. Empowering patient advocacy groups would be beneficial in recognizing any shortcomings of the plan and to divert resources accordingly.
format Article
id doaj-art-4ea7055c44df47a485394964c6228f7c
institution DOAJ
issn 0030-9982
language English
publishDate 2024-10-01
publisher Pakistan Medical Association
record_format Article
series Journal of the Pakistan Medical Association
spelling doaj-art-4ea7055c44df47a485394964c6228f7c2025-08-20T02:40:43ZengPakistan Medical AssociationJournal of the Pakistan Medical Association0030-99822024-10-01741110.47391/JPMA.10726Low availability of haematin (hemin) in PakistanFatima Ahsan0Muhammed Ifham Mohamed Imtiyas1Abdul Raheem Rizvie22nd Year MBBS Student, Jinnah Sindh Medical University, Karachi, Pakistan 5th Year MBBS Student, Jinnah Medical and Dental College, Karachi, Pakistan2nd Year MBBS Student, Jinnah Sindh Medical University, Karachi, Pakistan Madam, Acute Intermittent Porphyria (AIP) is an autosomal dominant disorder that results from a defect in the enzyme named porphobilinogen deaminase.1 It is symptomatic porphyria, involving the accumulation of porphyrins and porphyrin precursors due to impaired conversion in haeme synthesis. Acute Intermittent Porphyria is clinically characterized by acute episodes of multiple gastrointestinal and neurologic symptoms; during which the patient remains healthy between episodes.2 Acute Intermittent Porphyria episodes are commonly observed in post pubertal females. The most common symptoms include periodic abdominal pain, vomiting and hypertension followed by neurologic damage that leads to peripheral and autonomic neuropathies (mostly motor) and psychiatric manifestations.2 Hormonal cycle regulation may worsen porphyria, since its symptoms coincide with the menstrual cycle. Although positive response has been noted in hormonal suppression by gonadotropin releasing hormone agonists.3 Currently, the most widely used treatment is hemin, a form of haeme that can be given intravenously. Its administration reduces the haeme deficit, hence limits the production of porphyrins precursors by the body. Availability of hemin in Pakistan is not promising while alternatives such as intravenous infusion of glucose, and pain relievers like Nalbuphine, a man-made opioid analgesic, and Morphine are short-term treatments. Haeme Arginate (HA), a compound of haeme and arginine, is equivalent to hematin in the treatment of AIP. Long-term weekly intravenous infusions of prophylactic HA prevent severity and frequency of porphyric attacks in patients with AIP.4 While haeme therapy is recommended if a patient exhibits neurological impairment, liver transplant appears to be the last resort in patients with recurrent clinical manifestations. To effectively mediate the growing need of Hemin in Pakistan, a systematic plan with effective and immediate steps must be introduced. The regulatory authorities must expedite the approval and licensing process of appropriate medication that would meet the growing need of the country, while not compromising on its quality. The possibility of local production should be explored, while strengthening international ties aimed at importing affordable medication. The government should focus on initiating partnerships with international organizations, non-governmental organizations (NGOs) and global health initiatives. Nationwide workshops and informative campaigns towards healthcare work should be a priority, to raise awareness of the situation and the proper steps that should be taken to minimize its adverse effects. Empowering patient advocacy groups would be beneficial in recognizing any shortcomings of the plan and to divert resources accordingly. https://jpma.org.pk/index.php/public_html/article/view/10726Letter to the editorAcute intermittent porphyria
spellingShingle Fatima Ahsan
Muhammed Ifham Mohamed Imtiyas
Abdul Raheem Rizvie
Low availability of haematin (hemin) in Pakistan
Journal of the Pakistan Medical Association
Letter to the editor
Acute intermittent porphyria
title Low availability of haematin (hemin) in Pakistan
title_full Low availability of haematin (hemin) in Pakistan
title_fullStr Low availability of haematin (hemin) in Pakistan
title_full_unstemmed Low availability of haematin (hemin) in Pakistan
title_short Low availability of haematin (hemin) in Pakistan
title_sort low availability of haematin hemin in pakistan
topic Letter to the editor
Acute intermittent porphyria
url https://jpma.org.pk/index.php/public_html/article/view/10726
work_keys_str_mv AT fatimaahsan lowavailabilityofhaematinhemininpakistan
AT muhammedifhammohamedimtiyas lowavailabilityofhaematinhemininpakistan
AT abdulraheemrizvie lowavailabilityofhaematinhemininpakistan